| Firm | Analyst |
|---|---|
|
Barclays
|
Eliana Merle |
|
BofA Securities
|
Tazeen Ahmed |
|
B. Riley Securities
|
Mayank Mamtani |
|
Brookline Capital Markets
|
Leah Cann |
|
BTIG
|
Jeet Mukherjee |
|
Canaccord Genuity
|
Edward Nash |
|
Citi
|
Geoff Meacham |
|
Guggenheim
|
Brad Canino |
|
HC Wainwright
|
Andrew Fein |
|
Jefferies
|
Faisal Khurshid |
|
JP Morgan
|
Brian Cheng |
|
Leerink Partners
|
Thomas Smith |
|
Mizuho Securities
|
Joseph Catanzaro |
|
Morgan Stanley
|
Judah Frommer |
|
Oppenheimer & Co. Inc.
|
Jeff Jones |
|
Piper Sandler
|
Biren Amin |
|
RBC Capital Markets
|
Brian Abrahams |
|
Stephens
|
Sudan Loganathan |
|
Stifel
|
Alex Thompson |
|
TD Cowen
|
Marc Frahm |
|
Truist Securities
|
Kripa Devarakonda |
|
UBS Securities
|
David Dai |
|
Wells Fargo
|
Derek Archila |
|
Wolfe Research
|
Andy Chen |
Kymera Therapeutics, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Kymera Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kymera Therapeutics, Inc. or its management. Kymera Therapeutics, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.